Understand the source comparison
Body Recomposition Peptides 2026 Update: Compound Comparison
Below is a comparison of the peptides most commonly referenced in body recomposition research as of 2026. This table synthesizes published trial data, documented mechanisms, and practical considerations. Survodutide GLP-1/glucagon dual agonist. Enhances lipoly
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Below is a comparison of the peptides most commonly referenced in body recomposition research as of 2026. This table synthesizes published trial data, documented mechanisms, and practical considerations.
- Survodutide
- GLP-1/glucagon dual agonist. Enhances lipolysis while preserving mTOR signaling in muscle tissue
- +2.1% lean mass vs baseline (Phase III)
- −14.3% total body weight, ~92% from fat
- Subcutaneous injection, weekly
- Strongest evidence for lean tissue preservation during aggressive deficit. Nausea common during titration.
- Mazdutide
- GLP-1/GIP/glucagon tri-agonist. Amino acid partitioning favors muscle over adipose
- +1.8% lean mass despite 16.8% total weight loss
- −16.8% body weight, 85% adipose tissue
- Superior fat-to-lean ratio in clinical trials. GIP component may enhance insulin sensitivity more than survodutide.
- Follistatin-344
- Myostatin antagonist. Blocks GDF-8 inhibition of satellite cell proliferation
- +3.2kg lean mass in older adults without structured training
- Minimal direct fat loss (indirect via increased RMR)
- Intramuscular injection, bi-weekly
- Requires pharmaceutical-grade sourcing. Most effective in populations with elevated baseline myostatin.
- CJC-1295 + Ipamorelin
- GHRH analog + selective GH secretagogue. Increases endogenous GH and IGF-1
- +1.6–2.2kg lean mass with resistance training
- −3.8% body fat percentage over 16 weeks
- Subcutaneous injection, daily or 5 days/week
- Effect amplifies training stimulus but doesn't replace it. Minimal impact without structured hypertrophy protocol.
- MK 677
- Non-peptide ghrelin mimetic. Oral GH secretagogue
- +1.2–1.8kg lean mass over 6 months
- Modest (−2.1% body fat)
- Oral capsule, once daily
- Oral bioavailability is the advantage. Insulin resistance risk above 25mg/day. Water retention common.